Who are the key players in North America Companion Diagnostics Market industry?

The top five key players in the North America Companion Diagnostics Market are Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, and Qiagen. These companies lead the market through extensive research and development, wide product portfolios, strategic partnerships, and pioneering advancements in precision medicine and biomarker testing.

Which segment accounted for the largest North America Companion Diagnostics Market share?

The oncology application segment holds the largest share of the North America Companion Diagnostics Market. This dominance is driven by the rising use of companion diagnostics in personalized cancer therapies, enabling more precise treatment decisions, especially for lung, breast, and colorectal cancer patients.

What are the factors driving the North America Companion Diagnostics Market?

Key factors driving the market include the rising incidence of cancer, growing demand for personalized medicine, and increased regulatory approvals. For example, Abbott's regulatory advancements in CDx technology have pushed innovation and accelerated adoption among clinicians, significantly boosting market momentum.

Which type accounted for the largest North America Companion Diagnostics Market share?

Assay kits and reagents account for the largest market share by type in the North America Companion Diagnostics Market. Their dominance is attributed to frequent usage in a range of testing procedures, and the continual launch of new, more advanced assays by major players like Thermo Fisher Scientific.

Home Healthcare

North America Companion Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Companion Diagnostics Market
Brand: Bussiness Insights

North America Companion Diagnostics Market: by Type (Assays, Kits, Reagents, Instruments, Software & Services, Others), Application (Oncology, Neurology, Infectious Diseases, Cardiology, Autoimmune Diseases, Others), Distribution Channels (Hospital Laboratories, Commercial Service Providers, Reference Laboratories, Academic Medical Centers, Others), Technology (Polymerase Chain Reaction, In-situ Hybridization, Immunohistochemistry, Next-generation Sequencing, Gene Sequencing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20252

North America Companion Diagnostics Market Analysis, 2025–2035

The North America Companion Diagnostics Market is projected to witness sustained growth due to rising adoption of precision medicine, integration of next-generation sequencing technologies, and expanding clinical applications. Increased collaborations between biopharma and diagnostics firms, favorable regulatory landscapes, and investments in personalized healthcare are among the key factors driving the market. Notable advances in oncology, especially for targeted therapies, as well as emerging uses in neurology and infectious diseases, are further accelerating market expansion into new therapeutic areas. Innovation by leading companies is expected to enable robust revenue growth through 2035.

Latest Market Dynamics

Key Drivers

Growing demand for personalized medicine driven by oncology therapeutics, with Roche Diagnostics launching new FDA-approved companion assays in early 2024.
Advancement in next-generation sequencing (NGS) platforms, led by Thermo Fisher Scientific

Integration of artificial intelligence for biomarker discovery and diagnostics workflow automation, as exemplified by Illumina Inc.'s AI capabilities integrated into clinical genomic testing in 2024.
Strategic collaborations between pharmaceutical and diagnostic companies, such as the recent partnership between Abbott Laboratories and major pharma players in June 2024 to co-develop novel companion diagnostic assays.

High cost and complexity of multi-marker and gene panel tests, cited in Foundation Medicine’s mid-2024 report outlining reimbursement and implementation hurdles for multiplex diagnostics.
Regulatory uncertainties in approval pathways for emerging companion diagnostics, highlighted by the experience of Myriad Genetics in US-FDA and Health Canada’s evolving frameworks for complex tests in 2024.

In 2025, the North America Companion Diagnostics Market continues to be dominated by assays, followed by kits and reagents. The increasing prevalence of targeted therapies and the need for validated biomarkers drive assay demand. Kits and reagents, essential for streamlined and rapid testing, hold significant market shares, while instruments and software/services also show growing presence as the industry moves toward integrated workflows and digital diagnostics. The strong emphasis on clinical utility and regulatory compliance fuels continued product innovation and portfolio diversification, allowing manufacturers to address a spectrum of testing needs in hospital and reference laboratory settings.

Oncology applications command the largest market share in North America's companion diagnostics landscape in 2025, reflecting the region’s focus on targeted cancer therapies and precision medicine. Infectious diseases represent the second-largest segment, driven by rising adoption of advanced diagnostic tests for pathogen detection and pandemic preparedness. Neurology and cardiology are fast-growing application areas, bolstered by increasing biomarker discovery and new assay launches. Autoimmune diseases and ‘others’ provide steady market contributions, further diversifying the application spectrum and supporting ongoing growth across therapeutic verticals.

The North America Companion Diagnostics Market demonstrates a robust revenue trajectory from 2020 to 2035. After achieving a market size of $3,120 Million in 2025, projections indicate consistent double-digit CAGR, propelled by innovations in molecular diagnostics and the rapid integration of NGS-based assays. Annual revenue gains reflect increased payer acceptance, greater test volumes from expanded therapeutic indications, and widening access through commercial and hospital laboratories. The forecast underscores the vital contribution of the US, followed by Canada and Mexico, to the region’s sustained market growth.

Year-over-year (YoY) growth for the North America Companion Diagnostics Market remains robust, with peak acceleration observed in the mid-2020s, supported by regulatory approvals and rapid uptake of new technological platforms. Growth moderates from the early 2030s as market maturity is reached, but a steady stream of innovation and expanding clinical use cases sustains healthy YoY gains through 2035.

The US overwhelmingly leads the North America Companion Diagnostics Market in 2025, accounting for more than three-quarters of regional revenues due to its advanced healthcare infrastructure, robust reimbursement environment, and concentration of diagnostic innovation. Canada holds a significant share owing to growing investments in molecular diagnostics and supportive government initiatives. Mexico, while representing a smaller proportion, shows strong potential for future market expansion driven by increasing awareness and adoption of precision diagnostics.

Roche Diagnostics asserts its leadership in the North America Companion Diagnostics Market in 2025, bolstered by a broad portfolio and continual innovation in oncology and NGS-based diagnostics. Abbott Laboratories and Thermo Fisher Scientific also capture substantial market shares, leveraging advanced platforms and extensive clinical networks. Agilent Technologies and Qiagen NV round out the region’s top five, distinguished by their comprehensive companion diagnostic offerings and deep expertise in genomic and proteomic test development.

Hospital laboratories represent the primary buyers of companion diagnostics in North America for 2025, reflecting the centralization of advanced testing services in major clinical environments. Commercial service providers—including standalone diagnostic laboratories—continue to expand their market share, supported by rising test outsourcing and accessibility initiatives. Reference laboratories and academic medical centers maintain vital roles as both clinical and research testing hubs, while an ‘others’ category includes niche and fast-growing buyer segments.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	3120
Regions	US, Canada, Mexico
Segments	By Type (Assays, Kits, Reagents, Instruments, Software & Services, Others); By Application (Oncology, Neurology, Infectious Diseases, Cardiology, Autoimmune Diseases, Others); By Distribution Channels (Hospital Laboratories, Commercial Service Providers, Reference Laboratories, Academic Medical Centers, Others); By Technology (Polymerase Chain Reaction, In-situ Hybridization, Immunohistochemistry, Next-generation Sequencing, Gene Sequencing, Others); By Organization Size (Small, Medium, Large)
Players	Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies Inc., Qiagen NV, Illumina Inc., Danaher Corporation, BioMerieux SA, Myriad Genetics Inc., Siemens Healthineers AG, Almac Group, ARUP Laboratories, Guardant Health, Foundation Medicine, Invitae Corporation

June 2024: Roche Diagnostics launched a new multiplex companion diagnostic assay for breast cancer approved by FDA, expanding precision oncology offerings.
July 2024: Guardant Health opened a new reference laboratory in the US focused on liquid biopsy CDx offerings, increasing accessibility for non-invasive testing.
August 2024: Abbott Laboratories announced a joint development agreement with a major pharmaceutical partner to accelerate biomarker-driven diagnostic test launches.
June 2024: Illumina Inc. integrated artificial intelligence into its NGS platforms for faster and more accurate biomarker identification in CDx applications.
July 2024: Qiagen NV debuted a next-generation companion assay for neurological biomarkers aimed at MS and Alzheimer’s, receiving expedited Health Canada approval.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America Companion Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Companion Diagnostics Market Analysis, 2025–2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

North America Companion Diagnostics Market Share by Type (2025)

North America Companion Diagnostics Market Share by Applications (2025)

North America Companion Diagnostics Market Revenue (2020-2035)

North America Companion Diagnostics Market YoY Growth (2020-2035)

North America Companion Diagnostics Market Regional Share (2025)

Leading Market Players in North America Companion Diagnostics (2025)

Companion Diagnostics Market—Buyer Share, North America (2025)

Study Coverage

Key Recent Developments

Frequently asked questions